Nav: Home

ESMO announces new award for achievements in immuno-oncology

February 09, 2017

Lugano, Feb. 9, 2017 - ESMO, the leading European professional organisation for medical oncology, has announced today a new award honouring individuals for outstanding achievements in the area of cancer immunotherapy.

"Immunotherapy is an exciting and rapidly evolving area in oncology. Recognising excellence in this emerging area is a duty and an honour for us, as the society of reference committed to improving outcomes for cancer patients," said ESMO President Fortunato Ciardiello.

The new ESMO Award for Immuno-Oncology is in memory of Professor Georges Mathé, a French oncologist and immunologist who performed the first bone marrow graft between unrelated donors in 1958.

"Georges Mathé was indeed a pioneer of immunotherapy but also one of the co-founders of ESMO in 1975, who had the vision that medical oncology would become one of the most exciting development areas for cancer medicine," said Christoph Zielinski, Chair of the ESMO Fellowship and Award Committee.

Immunotherapy, which engages the patient's own defences to fight cancer, has considerably changed the landscape of treatment options in the last few years. Professor Mathé worked in this field from the fifties to the eighties, anticipating the need of developing immunotherapy and applying it to cancer treatment.

"I am very proud that ESMO is honouring my father's achievements with this prestigious award, recognising the growing importance of immunotherapies applied to cancer care. As the descendant of one of ESMO's founders and immunotherapy pioneers, I am grateful for the appreciation of his work which has brought new hope for cancer patients," said Catherine Gaston-Mathé.

The first award will be presented at the ESMO Immuno-Oncology Congress in Geneva on 7 December 2017.

"ESMO has always maintained the visionary attitude of its founders," said Rolf A. Stahel, ESMO Past President and initiator of the ESMO immuno-oncology projects.

ESMO organised the very first educational meeting on the basics of immunology in 2007. In 2013 a series of smaller annual events dedicated to immune-oncology was started with the ESMO Symposium on Immuno-Oncology.

"In the light of recent developments, renewing our commitment to keeping oncologists up to date in such a rapidly evolving field, the now fully-fledged ESMO Immuno-Oncology Congress will be the ideal platform for all stakeholders interested in immunotherapy as a new way to treat cancer patients," Stahel said.

Basic, translational and clinical researchers, immunologists, oncology clinicians will be offered an expanded programme and focused sessions dedicated to different tumour types.

"From the basics of immunotherapies to the latest research results in different cancer types; from understanding different treatment options to management of toxicities and interpretation of new data, we aim to create the European community of immune-oncology stakeholders," said Stahel.

"Immunotherapy provides medical oncologists with another tool to treat cancer patients. The ESMO Immuno-Oncology Congress will help to increase the overall understanding of the potential of this therapy and its implications for clinical practice, today and in the future," said Professor George Coukos, Scientific Co-Chair of the congress, director of the Department of Oncology at the University Hospital of Lausanne (CHUV) and the Ludwig Cancer Research Centre, Lausanne, Switzerland.

"I think this is one of the most exciting fields to be working in today! There are very important developments in many disease types which could lead to a radical reduction in the relapse rate and therefore an increase in the cure of many cancers," explained Coukos.

"The launch of the ESMO Immuno-Oncology Congress together with the new award in memory of Georges Mathé reflects ESMO's commitment to help cancer physicians and researchers keep abreast of the latest developments in oncology, in an effort to bring innovative approaches to cancer patients," the ESMO President concluded.
-end-


European Society for Medical Oncology

Related Immunotherapy Articles:

Barrier Proteins in Tumors are Possible Key to Immunotherapy Success
By comparing variations in protein expression in tumor samples from a single melanoma patient, researchers from the Johns Hopkins Bloomberg~Kimmel Institute and the Memorial Sloan-Kettering Cancer Center say their findings have the potential to reveal some of the mechanisms underlying response or resistance to immunotherapy drugs.
Discovery could guide immunotherapy for lung cancer
Scientists have discovered a new type of immune cell that could predict which lung cancer patients will benefit most from immunotherapy treatment, according to a Cancer Research UK funded study* published today (Monday) in Nature Immunotherapy.
Genetic mutations predict patient response to immunotherapy
Results of a new clinical study establish particular genetic defects in tumors as clinical indicators for successful response to a type of immunotherapy called PD-1 blockade.
'Immunoswitch' particles may be key to more-effective cancer immunotherapy
Scientists at Johns Hopkins have created a nanoparticle that carries two different antibodies capable of simultaneously switching off cancer cells' defensive properties while switching on a robust anticancer immune response in mice.
Early research suggests first immunotherapy for mesothelioma on the horizon
Malignant pleural mesothelioma or MPM is a rare cancer, but its incidence has been rising.
More Immunotherapy News and Immunotherapy Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Teaching For Better Humans
More than test scores or good grades — what do kids need to prepare them for the future? This hour, guest host Manoush Zomorodi and TED speakers explore how to help children grow into better humans, in and out of the classroom. Guests include educators Olympia Della Flora and Liz Kleinrock, psychologist Thomas Curran, and writer Jacqueline Woodson.
Now Playing: Science for the People

#535 Superior
Apologies for the delay getting this week's episode out! A technical glitch slowed us down, but all is once again well. This week, we look at the often troubling intertwining of science and race: its long history, its ability to persist even during periods of disrepute, and the current forms it takes as it resurfaces, leveraging the internet and nationalism to buoy itself. We speak with Angela Saini, independent journalist and author of the new book "Superior: The Return of Race Science", about where race science went and how it's coming back.